Proactive Investors - Run By Investors For Investors

ValiRx given US patent boost for its lead therapeutic compound

VAL201 is currently in a Phase I/II study that is assessing safety and tolerability and its effect in the treatment of prostate cancer and other solid tumours
Prostate Cancer UK
So far, VAL201 has met and exceeds the predicted safety and tolerability criteria set for the trial

ValiRx PLC (LON:VAL) saw its shares tick higher on news it has received positive news regarding the US patent application for its lead therapeutic compound, VAL201.

The United States of America patent and trademark office has given notice of allowance for the US Patent Application No.14/575065, otherwise known by the snappy title “Anti-Androgen Peptides and Uses Thereof in Cancer Therapy".

READ: ValiRx given the green light to accelerate progress of prostate cancer drug after encouraging early results

VAL201 is currently in a Phase I/II study that is assessing safety and tolerability and its effect in the treatment of prostate cancer and other solid tumours.

The patent application covers the molecule and use of compounds in pharmaceutically acceptable products. The patent coverage also includes a wide variety of derivatives, modifications and analogues of the compounds and their mode of action; furthermore, the protection sought includes therapeutic formulations with associated delivery systems.

ValiRx said allowance of this US patent will represent one of the cornerstones of its commercial strategy, as ValiRx has already secured patent protection in several other territories, including Europe.

"It is timely and very exciting to receive this notification of allowance for the VAL201 patent,” said Satu Vainikka, the chief executive officer of ValiRx, who noted that the approval comes only weeks after the company received approval from the UK Medicines and Healthcare Products Regulatory Agency and Research Ethics Committee for the company to expand its VAL201.

READ: ValiRx awarded fifth US patent for VAL401 cancer drug

“This US allowance means we can proceed to strengthen the VAL201 patent portfolio and, once granted, will provide ValiRx with patent protection in all its largest commercial markets globally. ValiRx looks forward optimistically to its future prospects," he added.

In afternoon trading, ValiRX shares were 0.5%, or 0.02p higher at 4.88p, having eased back from a session peak of 6.10p.

 -- Adds share price --

View full VAL profile View Profile

ValiRx Plc Timeline

Related Articles

Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third
test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
September 25 2018
The drug developer had originally to recruit 80 people for the second part of its phase II study of its SNG001 treatment, but it will now assess 120 patients

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use